Will inter partes review speed US generic drug entry?

被引：11
|
作者：
Darrow, Jonathan J. [1 ,2 ]
Beall, Reed F. [1 ,2 ]
Kesselheim, Aaron S. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, PORTAL, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源：
NATURE BIOTECHNOLOGY | 2017年 / 35卷 / 12期
关键词：
D O I：
10.1038/nbt.4036
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.
引用
收藏
页码：1139 / 1141
页数：3
相关论文
共 50 条
  • [21] PREJUDICIAL OR PROBATIVE: DETERMINING THE ADMISSIBILITY OF DECISIONS IN INTER PARTES REVIEW PROCEEDINGS
    Sawyer, Audra
    [J]. BOSTON UNIVERSITY LAW REVIEW, 2018, 98 (01) : 263 - 301
  • [22] What you need to know about Inter Partes Review proceedings
    Poplin, Justin
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [23] Opposing a granted patent in the USA: post grant and inter partes review
    Ragusa, Paul A.
    Zhang, Zichao
    [J]. PHARMACEUTICAL PATENT ANALYST, 2019, 8 (03) : 61 - 63
  • [24] Generic Entry, Reformulations and Promotion of SSRIs in the US
    Haiden A. Huskamp
    Julie M. Donohue
    Catherine Koss
    Ernst R. Berndt
    Richard G. Frank
    [J]. PharmacoEconomics, 2008, 26 : 603 - 616
  • [25] Generic entry, reformulations and promotion of SSRIs in the US
    Huskamp, Haiden A.
    Donohue, Julie M.
    Koss, Catherine
    Berndt, Ernst R.
    Frank, Richard G.
    [J]. PHARMACOECONOMICS, 2008, 26 (07) : 603 - 616
  • [26] Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry
    Morton, FMS
    [J]. INTERNATIONAL JOURNAL OF INDUSTRIAL ORGANIZATION, 2000, 18 (07) : 1085 - 1104
  • [27] Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs
    Murimi-Worstell, Irene B.
    Ballreich, Jeromie M.
    Seamans, Marissa J.
    Alexander, G. Caleb
    [J]. PLOS ONE, 2019, 14 (11):
  • [28] ENTRY THREATS AND PRICING IN THE GENERIC DRUG INDUSTRY
    Tenn, Steven
    Wendling, Brett W.
    [J]. REVIEW OF ECONOMICS AND STATISTICS, 2014, 96 (02) : 214 - 228
  • [29] Generic drug approval: A US perspective
    Nagori, B. P.
    Mathur, V.
    Garg, S.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 541 - 545
  • [30] Collusion in the US generic drug industry
    Clark, Robert
    Fabiilli, Christopher
    Lasio, Laura
    [J]. INTERNATIONAL JOURNAL OF INDUSTRIAL ORGANIZATION, 2022, 85
12345